Aotearoa New Zealand · Independent information vehicle

Ibogaine in New Zealand: the science, the regulation, and the capital behind it.

New Zealand has allowed prescribed, medically supervised ibogaine since 2009 — years before Washington began fast-tracking it. We track the science, the policy, and the capital now moving into iboga-derived medicine.

Clinical illustration of a translucent brain with glowing neural pathways beside iboga root bark and an ECG trace

Research and public information

What research reports about ibogaine.

Ibogaine is an alkaloid from the root bark of Tabernanthe iboga, a shrub native to Central West Africa and central to the Bwiti spiritual tradition of Gabon.[Nat. Prod. Rep. 2021] It is not a recreational experience and not a quick fix.

People describe two phases: a long visionary state of dreamlike, autobiographical recall, followed by a quieter reflective period of days or weeks where the psychological work happens. For opioid dependence, the most consistent reported effect is the interruption of withdrawal and craving — an opening, not a cure. Similar reports extend to alcohol, cocaine, and methamphetamine, though the evidence is more preliminary.[Molecules 2026 scoping review]

Research also points to a biological reset. Ibogaine and its metabolite noribogaine appear to promote neuroplasticity — the brain's ability to rewire pathways — and to normalise dopamine signalling disrupted by long-term substance use.[Front. Pharmacol. 2025] In effect, the reward circuitry may be restored closer to its pre-addiction baseline, which helps explain why craving and withdrawal can diminish so rapidly after a single supervised session. In veterans with traumatic brain injury, a single magnesium-supported session produced sustained improvements in functioning, PTSD, depression and anxiety.[Nature Medicine 2024]

In New Zealand, ibogaine is an unapproved medicine that a doctor may prescribe under Section 25 of the Medicines Act.[Medsafe, Section 25] That means a prescriber, screening, and medical supervision — not mail order, and not self-treatment.

Screening in clinical protocols

Published protocols describe cardiac assessment including ECG, medication review, and evaluation of liver and heart conditions before administration.

Clinical oversight reported

Research reports describe prescribing oversight, observation of cardiac measures, and structured follow-up as parts of medically supervised settings.

Global Shift

Industry News
Research / Funding

NIDA funds Brigham and Women's Hospital ibogaine study for opioid use disorder

The US National Institute on Drug Abuse has awarded Mass General Brigham a grant — an initial tranche of about US$2.3 million within an award worth up to roughly US$11 million — to seek FDA clearance for what would be the first federally funded, FDA-regulated clinical investigation of ibogaine in the United States. The Phase 1 study would evaluate safety and pharmacokinetics in healthy volunteers with extensive cardiac monitoring.

Psychedelic AlphaOriginal source

Intellectual Property / Canada

Clearmind publishes three US patent applications covering ibogaine, LSD and ketamine combinations

Clearmind Medicine announced the US publication of three patent applications covering combinations of LSD, ketamine and ibogaine with N-acylethanolamines such as palmitoylethanolamide, addressing potential uses across mental-health and substance use disorders. The filings extend the company's collaboration with NeuroThera Labs and signal continued commercial positioning around psychedelic-derived compounds.

BioSpaceOriginal source

Capital / Texas

Psyence BioMed commits up to US$5M to PsyLabs alongside a US$9M share exchange

Psyence Biomedical has agreed to invest up to US$5 million in Psyence Labs — US$2.4 million already committed — together with a value-matched share exchange of about US$9 million on each side, to support manufacturing and development capabilities for its planned US ibogaine programme. The company is evaluating a potential ibogaine clinical trial in Texas for opioid use disorder through its new Texas Ibogaine Research Corporation subsidiary.

GlobeNewswireOriginal source

Browse the full news archive
US$150k
Per kilogram, medical-grade ibogaine
$150m+
Texas state and federal money committed in 2026
Since 2009
Legal by prescription in New Zealand

Risk disclosure

Cardiac risk is the reason supervision is not optional.

Ibogaine prolongs the QT interval and has been associated with fatal arrhythmia, particularly alongside other drugs, electrolyte imbalance, or undiagnosed heart disease. Co-administered magnesium is being studied as a mitigation — the Stanford MISTIC protocol reported no serious cardiac adverse events under continuous monitoring — but that evidence supports careful medical settings, not unsupervised use. If you are in crisis in New Zealand, call or text 1737 to speak with a trained counsellor, free, any time.

Treatment Companion App · For prescribers and organisations

Clinical record support for ibogaine care.

A licensed clinical record platform for prescribers running ibogaine treatment. It organises medication readiness screening, cardiac and vital-sign values entered by clinicians (or by patients from separate home equipment), assessments, adverse event logging and follow-up in one record. Threshold prompts are configured by the clinician and require clinician review.

Screening

Medication readiness screening organised in one record for the treating clinician's review, before any course of care.

Vitals

Cardiac and vital-sign values entered by clinicians, or by patients from separate home equipment, kept in one record available for clinical review.

Alerting

Threshold prompts configured by the clinician — surfaced for their review and judgement, never acted on by the software itself.

Licensing for organisations

The platform is available under licence for clinics, research groups and sector organisations. Click the link to the app to see what is included and the licensing details.

Open the app

The app does not acquire patient data, monitor patients, diagnose, prescribe or alter medicines, and it does not replace clinical judgement or emergency care. Licensed for clinics, research groups and sector organisations. Ibogaine is a prescription medicine in New Zealand.

Start the Dialogue

Confidential inquiries for information, research, app licensing, or media.

Ibogaine NZ is an information resource. We do not provide medical advice, treatment referrals, or supply ibogaine at this stage. Please do not send clinical details.